JPIAMR-ACTION
Financiado
JPIAMR ANTIMICROBIAL TRANSMISSION INTERVENTIONS
In the past 90 years since their discovery, antibiotics have saved millions of lives from bacterial diseases. However, emerging resistance to antimicrobials now threatens many advances achieved in modern medicine. AMR is a critica...
In the past 90 years since their discovery, antibiotics have saved millions of lives from bacterial diseases. However, emerging resistance to antimicrobials now threatens many advances achieved in modern medicine. AMR is a critical global health issue tightly linked with the One Health concept, which recognises that human and animal health are inextricably linked, and that diseases are transmitted from humans to animals and vice versa. One Health also encompasses the environment as another link between humans and animals and a potential source and reservoir of AMR. Antimicrobial resistance is a growing global health concern and threatens the future treatment and health of humans and animals. In addition, AMR limits our ability to achieve several of the UN Sustainable Development Goals (SDGs). The global challenge to address AMR goes beyond the production of new antibiotics and therapies. Reducing demand for new antibiotics through public awareness, infection prevention and control, prudent and rational use of antibiotics for humans and animals, as well as effective diagnosis and surveillance of antibiotic-resistant infections and monitoring antibiotic use, are crucial when dealing with this problem globally. The transmission and spread of AMR in and between One Health compartments is complex, which emphasises the need for comprehensive interventions to reverse the trend of increasing human and animal infections resistant to treatment. The ERA-NET Cofund JPIAMR-ACTION will tackle this central challenge by supporting research and innovation for the development and testing of strategies and methodologies to reduce the transmission and spread of AMR within a full One Health spectrum. The JPIAMR-ACTION co-funded call and other activities will be instrumental in producing new innovative approaches, and advancing existing actions towards the development of new and improved interventions to inhibit or limit the development of AMR in humans, animals and the environment.
ver más
Duración del proyecto: 71 meses
Fecha Inicio: 2021-01-26
Fecha Fin: 2026-12-31
Fecha Fin: 2026-12-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2021-01-26
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
Presupuesto
El presupuesto total del proyecto asciende a
26M€
Líder del proyecto
VETENSKAPSRADET SWEDISH RESEARCH COUNCIL
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
387.21K€ |
Participante
181.91K€ |
Participante
389.81K€ |
Participante